We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluating the efficacy and safety of acotiamide in patients with esophagogastric junction outflow obstruction: study protocol for an investigator-initiated, multi-center, randomized, double-blind, placebo-controlled phase II trial.
- Authors
Esaki, Mitsuru; Ihara, Eikichi; Manabe, Noriaki; Kawami, Noriyuki; Iwakiri, Katsuhiko; Akiyama, Junichi; Kuribayashi, Shiko; Uraoka, Toshio; Ogino, Haruei; Chinen, Takatoshi; Misumi, Akiko; Watanabe, Hiroko; Suzuki, Maya; Kishimoto, Junji; Ogawa, Yoshihiro
- Abstract
Background: We have determined that the impaired accommodation of the lower esophageal sphincter (LES) underlies the pathogenesis of esophagogastric junction outflow obstruction (EGJOO). We have also found that acotiamide may treat EGJOO by improving impaired LES accommodation. The effects of acotiamide in patients with EGJOO need to be further confirmed in a prospective study. Methods: This trial is a multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of acotiamide (300 mg/day or 600 mg/day) with those of a placebo in the treatment of patients with EGJOO. The primary endpoint will be the proportion of patients who report an improvement in symptom of food sticking in the chest after 4 weeks of treatment period 1. The secondary endpoints will be the proportion of patients with normalized integrated relaxation pressure (IRP), the value of change from baseline in the distal contractile integral, basal LES pressure, EGJOO–quality of life score, Gastrointestinal Symptom Rating Scale, and the correlation between IRP and each symptom score. During the 2-year trial period, 42 patients from five institutions will be enrolled. Discussion: This trial will provide evidence to clarify the efficacy and safety of acotiamide as a treatment for patients with EGJOO. Acotiamide might help improve the quality of life of patients with EGJOO and is expected to prevent the progression of EGJOO to achalasia. Trial registration: This study was approved by the Institutional Review Board (IRB) of Kyushu University Hospital as well as the local IRBs of the participating sites for clinical trials and registered in the Japan Registry of Clinical Trials (jRCT: 2071210072). The registration date is on October 11, 2021. Article summary: Strengths and limitations of this study: This is the first prospective and randomized controlled trial to investigate the superiority of acotiamide over a placebo in the treatment of patients with EGJOO. The trial provides evidence that acotiamide can be used as a treatment for patients with EGJOO. Long-term outcomes cannot be assessed because this trial focuses on the short-term outcomes of acotiamide for the treatment of patients with EGJOO.
- Subjects
ESOPHAGOGASTRIC junction; PATIENT safety; PLACEBOS; SAFETY; RESEARCH protocols; ESOPHAGEAL motility disorders
- Publication
Trials, 2023, Vol 24, Issue 1, p1
- ISSN
1745-6215
- Publication type
Article
- DOI
10.1186/s13063-023-07468-w